B+
Bull case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
EVH
Evolent HealthANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$4.80
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.10
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+79.6
Score
AI commentary
The post-earnings setup is mixed: primary company evidence shows strong revenue growth and higher guidance, but weaker adjusted EBITDA margins and elevated medical costs. The available August 7 price snapshot was positive, while analyst revisions, options, short-interest, employee, and social data are unavailable; confidence therefore remains limited despite the constructive long-term outlook.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 2026 results and raised 2026 guidanceHigh impact
Q2 revenue increased to $652.5 million from $444.3 million, while adjusted EBITDA declined to $28.1 million from $37.5 million. Evolent raised 2026 revenue guidance to $2.6-$2.7 billion and set adjusted EBITDA guidance at $120-$135 million [#SEC-8K-2026-08-06].
2026-09-30catalystMedical-cost and execution pressureHigh impact
Q2 adjusted EBITDA margin fell to 4.3% from 8.5%, while the medical expense ratio rose to 95.3% from 80.0%. Medicaid and client-specific membership attrition remain explicit industry headwinds [#SEC-8K-2026-08-06].
2027-08-08catalystOncology Performance Suite launchHigh impact
A planned oncology partnership covering approximately 1.5 million lives is expected to launch by December 2026, subject to regulatory approvals, with approximately $300 million of annualized revenue potential [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology